Abstract
A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay
Highlights
Since the availability of the serum free light chain assay, the diagnosis, monitoring and prognosis for plasma cell dyscrasias has greatly improved, because the κ/λ ratio represents a sensitive balance between the two types of light chain [1]
The Sebia monoclonal FLC concentrations were consistent with the M protein concentrations determined with the serum protein electrophoresis (SPE)
Method comparison κFLC and λFLC were measured in 510 sera using both Sebia FLC and Freelite
Summary
Since the availability of the serum free light chain (sFLC) assay, the diagnosis, monitoring and prognosis for plasma cell dyscrasias has greatly improved, because the κ/λ ratio represents a sensitive balance between the two types of light chain [1]. Overexpression of a light chain type by a malignant B-cell clone leads to a shift in the κ to λ ratio reference range [2] so that it is possible to identify affected patients before the disease has progressed to the extent that BenceJones proteinuria becomes detectable in the urine. This has led to the inclusion of the determination of FLC in the guidelines for the diagnosis, treatment and follow-up of multiple myeloma [3]. The new quantitative s-FLC ELISA (Sebia) was tested for its suitability for use in routine clinical diagnostics in an application study in a supraregional laboratory center in Germany
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
